



Job Title: COPD / Asthma Pre-clinical Scientist

Location: Munich

Start Date: April/May 2026

Job Type: Permanent Contract

Role Summary

RN.AI Therapeutics GmbH is seeking a PhD-level Pre-clinical Scientist with a strong background in COPD, Asthma, and other immunology and inflammatory (I&I) diseases. The role focuses on drug discovery and early development of novel combination therapies enabled by AI-driven target identification and combination therapy development. This is a company-oriented role suited for candidates motivated to translate science into therapies rather than pursue purely academic research.

Key Responsibilities

- Design and execute pre-clinical in vitro and in vivo studies relevant to COPD, asthma, and other I&I diseases.
- Support target validation and mechanism-of-action studies for mono- and bispecific antibody programs.
- Collaborate closely with AI and computational teams to translate AI-identified target combinations into experimentally testable hypotheses.
- Interpret disease biology using human-relevant disease models
- Contribute to candidate selection, data packages, and internal go/no-go decision-making in early drug development.
- Participate in biology strategy discussions spanning respiratory and broader immunology and inflammatory diseases.
- Work cross-functionally with antibody engineering, biology, and leadership teams

Required Qualifications

- PhD/Post-Doc in Immunology, Pulmonary Biology or related life science discipline.
- Hands-on experience in COPD, Asthma, or I&I disease models (academic or industry).
- Entry-level industry experience acceptable; prior involvement in drug discovery or pre-clinical development strongly preferred.
- Understanding of antibody-based therapeutics; experience with bispecific antibodies is a strong advantage.
- Strong data-driven mindset with ability to interpret complex datasets and AI outputs.
- Highly motivated, and collaborative to work in a company-oriented translational setting.

About RN.AI Therapeutics

RN.AI Therapeutics GmbH is a Helmholtz spin-off from Prof. Theis' lab in Munich, developing next-generation combination immunology therapies. By integrating AI-enabled drug development, the company addresses complex immunology and inflammatory diseases with high unmet medical need, starting in respiratory indications and expanding across the I&I landscape.

Interested candidates are invited to share their CV at justin.antony@rmai-tx.com

Name: RN.AI Therapeutics GmbH (HRB 304165)

Address: Helmholtz Pioneer Campus - Munich,
Ingolstädter Landstr. 1, 85764 Neuherberg

Phone: +49 176 31450468

Email: justin.antony@rmai-tx.com
info@rmai-tx.com